The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
Based on a scientifically solid proof of concept in dogs and cats, a licensed international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding and to become profitable within 36 months of raising funds.